Evidence map›Paper›PMID 27589530›Full record

ArticleJournal of Alzheimer's disease : JAD2016

Transcriptional Analysis of Blood Lymphocytes and Skin Fibroblasts, Keratinocytes, and Endothelial Cells as a Potential Biomarker for Alzheimer's Disease.

Marat A Mukhamedyarov, Albert A Rizvanov, Eduard Z Yakupov, Andrey L Zefirov, Andrey P Kiyasov, Helton J Reis, Antônio L Teixeira, Luciene B Vieira, Luciana M Lima, Ilnur I Salafutdinov and 5 more

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Frontiers in medicine · 2019
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Marat A MukhamedyarovKazan State Medical University, Kazan, Russia.
Albert A RizvanovKazan Federal University, Kazan, Russia.
Eduard Z YakupovKazan State Medical University, Kazan, Russia.
Andrey L ZefirovKazan State Medical University, Kazan, Russia.
Andrey P KiyasovKazan Federal University, Kazan, Russia.
Helton J ReisUniversidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Antônio L TeixeiraUniversidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Luciene B VieiraUniversidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Luciana M LimaUniversidade Federal de Viçosa, Viçosa, Brazil.
Ilnur I SalafutdinovKazan Federal University, Kazan, Russia.
Elena O PetukhovaKazan State Medical University, Kazan, Russia.
Svetlana F KhaiboullinaKazan Federal University, Kazan, Russia.
Karen A SchlauchUniversity of Nevada, Reno, NV, USA.
Vincent C LombardiUniversity of Nevada, Reno, NV, USA.
András PalotásKazan Federal University, Kazan, Russia.

Funding

Outreach/Diversity/Pipeline ProjectP20GM103440 · NIGMS · UNIVERSITY OF NEVADA RENO · PI Julia Petereit · 2012 to 2026
$58.0M
NIGMS NIH HHS P20 GM103440
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a devastating and progressive form of dementia that is typically associated with a build-up of amyloid-β plaques and hyperphosphorylated and misfolded tau protein in the brain. Presently, there is no single test that confirms AD; therefore, a definitive diagnosis is only made after a comprehensive medical evaluation, which includes medical history, cognitive tests, and a neurological examination and/or brain imaging. Additionally, the protracted prodromal phase of the disease makes selection of control subjects for clinical trials challenging. In this study we have utilized a gene-expression array to screen blood and skin punch biopsy (fibroblasts, keratinocytes, and endothelial cells) for transcriptional differences that may lead to a greater understanding of AD as well as identify potential biomarkers. Our analysis identified 129 differentially expressed genes from blood of dementia cases when compared to healthy individuals, and four differentially expressed punch biopsy genes between AD subjects and controls. Additionally, we identified a set of genes in both tissue compartments that showed transcriptional variation in AD but were largely stable in controls. The translational products of these variable genes are involved in the maintenance of the Golgi structure, regulation of lipid metabolism, DNA repair, and chromatin remodeling. Our analysis potentially identifies specific genes in both tissue compartments that may ultimately lead to useful biomarkers and may provide new insight into the pathophysiology of AD.

Indexed as

AgedAlzheimer DiseaseBiomarkersEndothelial CellsFemaleFibroblastsHumansKeratinocytesLymphocytesMalePilot ProjectsTranscription, GeneticBiomarkersAlzheimer’s diseaseamyloidbiomarkerdiagnosticsearly diagnosisendothelial cellfibroblastinflammationkeratinocytelymphocytemild cognitive impairmentneurodegenerationoxidative stressskin biopsy

Identifiers

PMID27589530
PMCPMC5260811

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.